Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen – The New York Times
Business News
- Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen The New York Times
- House investigation says FDA approval process of Alzheimer’s drug was ‘rife with irregularities’ CNN
- FDA Faulted for Working Improperly With Biogen Before Clearing Alzheimer’s Drug The Wall Street Journal
- House investigation faults FDA, Biogen for Alzheimer’s drug approval The Washington Post
- Congressional report: U.S. FDA broke own protocols in approving Biogen Alzheimer’s drug Yahoo News
- View Full Coverage on Google News
Source: Business News